Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors
- 11 June 2020
- journal article
- research article
- Published by Elsevier BV in International Journal of Antimicrobial Agents
- Vol. 56 (2), 106055
- https://doi.org/10.1016/j.ijantimicag.2020.106055
Abstract
No abstract availableKeywords
Funding Information
- Jinan University
This publication has 51 references indexed in Scilit:
- Critical Assessment of the Important Residues Involved in the Dimerization and Catalysis of MERS Coronavirus Main ProteasePLOS ONE, 2015
- Ligand-induced Dimerization of Middle East Respiratory Syndrome (MERS) Coronavirus nsp5 Protease (3CLpro)Online Journal of Public Health Informatics, 2015
- Chalcones isolated fromAngelica keiskeiinhibit cysteine proteases of SARS-CoVJournal of Enzyme Inhibition and Medicinal Chemistry, 2015
- Structure-Based Design, Synthesis, and Evaluation of Peptide-Mimetic SARS 3CL Protease InhibitorsJournal of Medicinal Chemistry, 2011
- Discovery of the First Insect Nidovirus, a Missing Evolutionary Link in the Emergence of the Largest RNA Virus GenomesPLoS Pathogens, 2011
- Profiling of Substrate Specificity of SARS-CoV 3CLproPLOS ONE, 2010
- Three-dimensional domain swapping as a mechanism to lock the active conformation in a super-active octamer of SARS-CoV main proteaseProtein & Cell, 2010
- Two adjacent mutations on the dimer interface of SARS coronavirus 3C-like protease cause different conformational changes in crystal structureVirology, 2009
- Mechanism of the Maturation Process of SARS-CoV 3CL ProteaseJournal of Biological Chemistry, 2005
- 3C-like Proteinase from SARS Coronavirus Catalyzes Substrate Hydrolysis by a General Base MechanismBiochemistry, 2004